22nd Century Group earnings release, May 7, 2026
Exhibit
99.1
22nd
Century Group Reports First Quarter 2026 Financial Results
Continues
VLN®
Commercial Expansion with New Stores Selling Proprietary Branded VLN®
Products
Expanded
PMTA Portfolio and Licensing Strategy Designed to Unlock Further Retail Penetration Opportunities
MOCKSVILLE,
N.C., May 7, 2026 —22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the first quarter ended March 31, 2026, and provided an update on recent business highlights.
The
Company’s proprietary reduced nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reducing nicotine consumption. 22nd Century is focusing on smoker health and wellness by giving smokers an opportunity to control their tobacco consumption, rather than switching them to another highly addictive product like a vape or nicotine pouch.
“Following the initial Pinnacle VLN® distribution in the fourth quarter 2025, smokers began to gravitate to and are purchasing VLN® cigarettes in a growing number of geographies and stores,” said Larry Firestone, Chief Executive Officer of 22nd Century Group.
“Having accumulated a base of state authorizations across our portfolio of brands, we continue to focus on expanding our distribution and introducing smoking consumers to our VLN® products.
“As we capture sustained adult smoker adoption of VLN® products, we expect to expand both our retail and category footprint.
We are targeting to grow to more than 5,000 retail outlets by the end of 2026 by adding new retail partners across all classes of trade.
Supporting this effort, we have significantly advanced further sales efforts with additional retail partners seeking to add VLN® branded products to their line-ups.
“We believe we are the single commercial tobacco Company that is an ally of the FDA in their efforts to formally establish a low nicotine standard. Our technology and product roadmap is set to build out a robust portfolio of new tobacco products. These products will span multiple categories, creating a flexible and scalable platform that can accommodate evolving market preferences and continue to drive the low nicotine initiative in the regulatory environment. Our business model is set so that all current and any newly authorized combustible tobacco products in this expanded portfolio once authorized will be available for licensing, providing other tobacco companies with compliant, ready-to-market product pathways. This further reinforces 22nd Century’s position as the leader in regulatory-driven innovation within the combustible tobacco segment. This includes the development of our 100mm form factor product and the application of our proprietary low nicotine tobacco to categories such as filtered cigars, pouches and moist snuff.”
“By combining our proprietary plant biotechnology, FDA-authorized claims, expanded retail distribution, broader product categories and readily available licensing, 22nd Century intends to lead the transition away from highly addictive tobacco products and support adult smokers and tobacco users seeking meaningful change,” concluded Firestone.
First
Quarter 2026 Financial Results
(compared to Fourth Quarter 2025, except as noted)
All figures reported below reflect continuing operations, excluding discontinued operations related to the sale and exit of the Company’s hemp/cannabis business in late 2023, except as noted.
2026
Corporate Priorities
22nd
Century has identified the below priorities for its business activities in 2026:
The
Company believes the convergence of regulatory momentum, consumer awareness, and its differentiated product portfolio creates a compelling opportunity for long-term value creation.
Recent
Business Highlights
First
Quarter 2026 Product Line Net Revenues
Balance
Sheet
Conference
Call
22nd
Century will host a live webcast today at 8:00 a.m. E.T. to discuss its first quarter 2026 financial results and business highlights.
The live and archived webcast will be accessible in the Events section on 22nd Century’s Investor Relations website at https://ir.xxiicentury.com/events.
Summary
Financial Results
(dollars in thousands, except per share data)
Financial statements
Income Statement
Three Months Ended — (dollars in thousands, except per share data)
| Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Three Months Ended – Change – $$ | Three Months Ended – Change – % | |
|---|---|---|---|---|
| Revenues, net | 4,105 | 5,956 | -1,851 | -31.1% |
| Gross loss | -636 | -609 | -27 | 4.4% |
| Operating loss | -3,039 | -2,570 | -469 | 18.2% |
| Net loss from continuing operations | -3,019 | -3,274 | 255 | -7.8% |
| Basic and diluted loss per common share from continuing operations | -5.07 | -634.25 | 629.18 | -99.2% |
| Adjusted EBITDA (a) | -2,595 | -2,320 | -275 | -11.8% |
Income Statement
Three Months Ended — (amounts in thousands, except share and per-share data)
| Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | ||
|---|---|---|---|
| Revenues, net | 4,105 | 5,956 | |
| Cost of goods sold | 1,925 | 2,884 | |
| Excise taxes and fees on products | 2,816 | 3,681 | |
| Gross loss | -636 | -609 | |
| Operating expenses: | Sales, general and administrative | 2,118 | 1,799 |
| Operating expenses: | Research and development | 285 | 162 |
| Operating expenses: | Total operating expenses | 2,403 | 1,961 |
| Operating expenses: | Operating loss from continuing operations | -3,039 | -2,570 |
| Other income (expense): | Other expense | -162 | |
| Other income (expense): | Interest income | 31 | 16 |
| Other income (expense): | Interest expense | -11 | -558 |
| Other income (expense): | Total other income (expense), net | 20 | -704 |
| Other income (expense): | Loss from continuing operations before income taxes | -3,019 | -3,274 |
| Other income (expense): | Net loss from continuing operations | -3,019 | -3,274 |
| Discontinued operations: | Loss from discontinued operations before income taxes | -242 | -1,054 |
| Discontinued operations: | Net loss from discontinued operations | -242 | -1,054 |
| Discontinued operations: | Net loss | -3,261 | -4,328 |
| Discontinued operations: | Comprehensive loss | -3,261 | -4,328 |
| Discontinued operations: | Net loss | -3,261 | -4,328 |
| Discontinued operations: | Deemed dividends | -589 | |
| Discontinued operations: | Dividend for redemption of Series A Convertible Preferred Stock | -6,916 | |
| Discontinued operations: | Net loss available to common shareholders | -10,766 | -4,328 |
| Basic and diluted loss per share: | Basic and diluted loss per common share from continuing operations | -5.07 | -634.25 |
| Basic and diluted loss per share: | Basic and diluted loss per common share from discontinued operations | -0.41 | -204.18 |
| Basic and diluted loss per share: | Basic and diluted loss available to common shareholders per common share | -18.08 | -838.43 |
| Basic and diluted loss per share: | Weighted average shares outstanding - basic and diluted | 595,344 | 5,162 |
Balance Sheet
December 31, — (amounts in thousands, except share and per-share data)
| March 31, – 2026 | December 31, – 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 9,545 | 7,149 |
| Current assets: | Accounts receivable, net | 4,779 | 3,594 |
| Current assets: | Inventories | 4,346 | 4,326 |
| Current assets: | Prepaid expenses and other current assets | 2,400 | 2,562 |
| Current assets: | Total current assets | 21,070 | 17,631 |
| Current assets: | Property, plant and equipment, net | 2,366 | 2,440 |
| Current assets: | Operating lease right-of-use assets, net | 688 | 728 |
| Current assets: | Intangible assets, net | 6,137 | 6,224 |
| Current assets: | Other assets | 49 | |
| Current assets: | Total assets | 30,310 | 27,023 |
| Current liabilities: | Notes and loans payable-current | 113 | 204 |
| Current liabilities: | Operating lease obligations | 172 | 168 |
| Current liabilities: | Accounts payable | 1,025 | 1,000 |
| Current liabilities: | Accrued expenses and other current liabilities | 1,135 | 836 |
| Current liabilities: | Accrued excise taxes and fees | 3,525 | 3,343 |
| Current liabilities: | Contract liabilities | 1,936 | 1,721 |
| Current liabilities: | Total current liabilities | 7,906 | 7,272 |
| Long-term liabilities: | Notes and loans payable | 475 | 504 |
| Long-term liabilities: | Operating lease obligations | 556 | 601 |
| Long-term liabilities: | Other long-term liabilities | 155 | 154 |
| Long-term liabilities: | Total liabilities | 9,092 | 8,531 |
| Mezzanine equity: | Series A convertible preferred shares, $0.00001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at March 31, 2026 and 9,650 at December 31, 2025, respectively | 2,734 | |
| Mezzanine equity: | Total mezzanine equity | 2,734 | |
| Shareholders’ equity: | Capital in excess of par value | 423,404 | 414,683 |
| Shareholders’ equity: | Accumulated deficit | -402,186 | -398,925 |
| Shareholders’ equity: | Total shareholders’ equity | 21,218 | 15,758 |
| Shareholders’ equity: | Total liabilities, mezzanine equity and shareholders’ equity | 30,310 | 27,023 |
Full release
(a) Adjusted EBITDA is a non-GAAP financial measure. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures. Refer to Tables A at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.
Summary
Product Line Results
(in thousands)
About
22nd Century Group, Inc.
22nd
Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.
Our
Technology is Tobacco
Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.
Our
Products
We created our flagship product, the VLN® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption.
VLN® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.
FDA... (truncated)entific Foundation
VLN® low nicotine combustible cigarettes were authorized in December 2021, making them the first and still the only combustible cigarettes authorized by the U.S. Food and Drug Administration specifically to help reduce nicotine consumption.
Decades of independent clinical research and peer-reviewed studies—evaluated as part of the FDA’s Modified Risk Tobacco Product (MRTP) authorization process—demonstrated that reducing nicotine content can decrease nicotine intake, increase quit attempts, and reduce overall exposure to nicotine.
FDA-authorized
VLN® claims include:
VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC.
Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.
Learn more about VLN® at tryvln.com.
Cautionary
Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,”
“believe,” “consider,” “continue,” “could,” “estimate,” “expect,”
“explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,”
“may,” “plan,” “potential,” “predict,” “preliminary,” “probable,”
“project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives,
(ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements.
Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s
Annual Report on Form 10-K filed on March 26, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.
Notes regarding Non-GAAP Financial Information
In addition to the Company’s reported results in accordance with generally accepted accounting principles in the United States of
America (“GAAP”), the Company provides EBITDA and Adjusted EBITDA.
In order to calculate EBITDA, the Company adjusts net (loss) income by adding back interest expense (income), provision (benefit) for income taxes, and depreciation and amortization expense. Adjusted EBITDA consists of EBITDA adjusted by the Company for certain non-cash and/or non-operating expenses, including adding back equity-based employee compensation expense, restructuring and restructuring-related charges such as impairment, acquisition and transaction costs, and other unusual or infrequently occurring items, if applicable, such as inventory reserves and adjustments, gains or losses on disposal of property, plant and equipment, and gains or losses on investments.
The
Company believes that the presentation of EBITDA and Adjusted EBITDA are important financial measures that supplement discussion and analysis of its financial condition and results of operations and enhances an understanding of its operating performance. While management considers EBITDA and Adjusted EBITDA to be important, these financial performance measures should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating (loss) income, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company’s measurement of Adjusted EBITDA may not be comparable to those of other companies.
Investor
Relations & Media Contact
Matt
Kreps
Investor Relations
22nd Century Group investorrelations@xxiicentury.com
214-597-8200
22nd
CENTURY GROUP, INC.